– USA, CA – Acepodia, a clinical-stage biotechnology today announced the closing of a $109 million Series C financing round led by Digital Mobile Venture alongside new and existing investors.
Concurrent with the financing, Samuel Chen, Director at Digital Mobile Venture, will join the Acepodia Board of Directors. Mr. Chen is also the largest shareholder of Polaris Pharmaceuticals.
“This significant capital raise paves the way for us to deliver on our mission of bringing innovative, effective and affordable cell therapies to the broadest possible population of cancer patients,” said chairman and co-founder, Dr. Patrick Yang.
The funds will be used to further validate the company’s ACC technology and advance its pipeline of antibody cell effector therapies for patients with cancer with limited treatment options.
“We are pleased by the strong support and confidence of our investors as we initiate additional research and development programs and continue our clinical trial expansion in the U.S. in the coming years,” said CEO and co-founder, Dr. Sonny Hsiao. “We are also honored to welcome visionary technology investor Samuel Chen to our board of directors, who shares our mission of building a next-generation platform of cell therapies for cancers with high unmet needs.”
About Acepodia
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as gamma delta T cells and off-the-shelf natural killer cells to create novel antibody cell effector therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
Acepodia has raised $166 million to date in venture capital financing, including a $47 million Series B round completed in March 2021. Investors have included Ridgeback Capital Investments, 8VC, DEFTA Partners, CDIB Capital Healthcare, Maxpro, E-Sun Venture, BioEngine Venture, Samuel Chen, Yahoo founder Jerry Yang, and Foxconn founder Terry Gou.
For more information: https://www.acepodia.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
